Targeting this intricate crosstalk holds significant therapeutic potential, offering opportunities to selectively inhibit NRF2 in cancer cells while preserving its essential protective functions in normal tissues, thus minimizing collateral damage and improving treatment efficacy. This evidence concerns the gene NFE2L2 and cancer.